We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The Janssen Pharmaceutical Companies of Johnson & Johnson has made a strategic decision to discontinue the development of pimodivir, an investigational antiviral treatment for influenza A infection.
Research led by Georgia State University has enabled the development of a universal vaccine for influenza A viruses, proven to provide long-lasting immunity in mice.